Eli Lilly's diabetes treatment meets main goal in two late-stage studies

Eli Lilly and Co said on Tuesday its experimental diabetes treatment was shown to be as effective as the drugmaker’s Humalog medicine in two late-stage studies.

The study also found that the drug, Ultra Rapid Lispro, significantly improved post-meal blood sugar levels in people with both type 1 and type 2 diabetes and had a similar safety profile as Humalog.